Point-CounterpointChimeric Antigen Receptor T-cell Therapy for First Relapse in Multiple Myeloma: A Promising Strategy
Author:
Open Access
- 10 April 2024
- journal article
- research article
- Published by American Society of Hematology in The Hematologist
- Vol. 21 (3)
Abstract
Chimeric antigen receptor T-cell (CAR-T) therapy has heralded a transformative era in the treatment of multiple myeloma (MM) following the first relapse. I Chimeric antigen receptor T-cell (CAR-T) therapy has heralded a transformative era in the treatment of multiple myeloma (MM) following the first relapse. IKeywords
This publication has 8 references indexed in Scilit:
- Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaNew England Journal of Medicine, 2023
- CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.Journal of Clinical Oncology, 2023
- Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2.Journal of Clinical Oncology, 2023
- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaNew England Journal of Medicine, 2023
- P-240: Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the SEER-Medicare databaseClinical Lymphoma Myeloma and Leukemia, 2022
- P899: REAL-WORLD ASSESSMENT OF TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE OPTUM DATABASEHemaSphere, 2022
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyThe Lancet, 2021
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaNew England Journal of Medicine, 2021